Key facts
- FIZE Medical’s last known valuation is $73.1M (Aug 2022).
- It has raised $38.9M; the latest was Later Stage VC in Nov 2025.
- Notable investors include Eldan Molecular Imaging, Hibiscus Capital Management, Mendham Investment Group, Rapha Capital Management, Teshuva Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for FIZE Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for FIZE Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FIZE Medical
Developer of a medical device designed to measure key indicators of the health status of patients found in their urine. The company's device offers real-time monitoring of urine production, enabling clinics and hospitals to detect early indicators of patient status to save lives and prevent complications.
- Sector
- Healthcare
- HQ
- Modiin-Maccabim-Reut, Israel
- Founded
- 2014
- Employees
- 50
- Website
- fizemedical.com/
- Ownership
- Privately Held (backing)
FIZE Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FIZE Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FIZE Medical in its N-PORT filings yet. We sweep new filings monthly.